CND Life Sciences Secures $13.5M Series A to Transform Neurodegenerative Disease Diagnostics with the Syn-One Test®

We are thrilled to announce that CND Life Sciences has successfully raised $13.5 million in fresh capital to further its mission of advancing the care of patients suffering from neurodegenerative diseases. Based in Scottsdale, AZ, and operating a CLIA-certified and CAP-accredited laboratory, CND Life Sciences is at the forefront of revolutionizing diagnostic testing for conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company’s pioneering Syn-One Test® is the first commercially available test designed to detect, visualize, and quantify misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This groundbreaking diagnostic tool utilizes three small in-office skin biopsies to offer clinicians a convenient, accurate, and minimally invasive alternative for confirming synucleinopathy in patients. The newly secured funding will bolster ongoing research and development efforts, expand the company’s operational capabilities, and enhance collaboration with multiple biopharmaceutical partners. By investing in cutting-edge technology and strengthening its research collaborations, CND Life Sciences is poised to further advance the science behind neurodegenerative disease diagnostics and ensure that patients receive faster, more precise diagnoses. The infusion of capital underscores investor confidence in the company’s innovative approach and its impact on patient care. As CND continues to push the boundaries of medical innovation, this investment will play a critical role in driving forward clinical studies, scaling the Syn-One Test® availability, and ultimately contributing to improved patient outcomes in a critical area of unmet clinical need. This milestone marks a significant step toward transforming the landscape of neurodegenerative disease diagnostics and patient care worldwide.